Tolerogenic Interactions of 4-1BB

4-1BB 的耐受性相互作用

基本信息

  • 批准号:
    7771080
  • 负责人:
  • 金额:
    $ 23.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-10 至 2011-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The failure of T cell tolerance can lead to spontaneous inflammation and at worst autoimmune disease. The control of T cell tolerance versus immunity in part relies on signals from co-stimulatory and co-inhibitory receptors that control various activities of T cells. 4-1BB (CD137, ILA, TNFRSF9), a member of the tumor-necrosis factor receptor (TNFR) super-family, was originally identified as an inducible co-stimulatory molecule on activated T cells. The ligand of 4-1BB (4-1BBL, TNFSF9), a member of the TNF super-family, expressed on activated APC binds to 4-1BB that is induced on T cells, generating positive signals inside T cells to help them function and to augment various aspects of immunity. In contrast we have found an inhibitory role for 4-1BB that does not rely on interaction with 4-1BBL. The absence of 4-1BB, in gene-deficient animals, leads to an enhanced rather than suppressed responsiveness of T cells to specific antigen, and 4-1BB-deficient mice spontaneously generate autoimmune-type phenotypes with chronic inflammation at the mucosal interfaces, a phenotype not seen in 4-1BBL-deficient mice. Our hypothesis is that 4-1BB binds with unidentified ligands that are constitutively expressed or induced early in an immune response to limit T cell reactivity and maintain tolerance, but by switching partners to 4-1BBL expressed later with inflammation, 4-1BB can then provide a positive stimulatory action. Our preliminary results have identified both galectin-3 and galectin-9, two reported suppressive molecules, as partners for 4- 1BB. The studies in this grant will investigate the interaction of galectins with 4-1BB and determine whether 4-1BB/galectin interactions account for 4-1BB negatively regulating T cell responsiveness. The identification and characterization of novel binding partners for 4-1BB will provide new understanding into 4-1BB biology as well as T cell tolerance and chronic inflammation. PUBLIC HEALTH RELEVANCE: 4-1BB and its ligand(s) are expressed on the surface of many immune cells and are thought to regulate the ability to mount an immune response. 4-1BB provides essential signals to a T cell to allow it to continue dividing late in its response, and to suppress excessive death. However, 4-1BB interactions also act as a rate-limiting step to control initial T cell division and expansion. By understanding where and when 4-1BB and its ligand(s) are expressed, and the functional importance of these putative interactions, we will gain knowledge that might lead to ways to either enhance or suppress T cell responses, and so might be therapeutically relevant in a number of disease settings such as in limiting autoimmunity, or augmenting the ability to respond to cancerous cells or infectious pathogens.
描述(由申请人提供):T细胞耐受性的失败可导致自发性炎症,最严重的是自身免疫性疾病。T细胞耐受性相对于免疫性的控制部分依赖于来自控制T细胞的各种活性的共刺激和共抑制受体的信号。4-1BB(CD 137,ILA,TNFRSF 9)是肿瘤坏死因子受体(TNFR)超家族的成员,最初被鉴定为活化T细胞上的可诱导共刺激分子。4-1BB(4-1BBL,TNFSF 9)的配体是TNF超家族的一员,在活化的APC上表达,与T细胞上诱导的4-1BB结合,在T细胞内产生阳性信号,以帮助它们发挥功能并增强免疫力的各个方面。相反,我们发现4-1BB的抑制作用不依赖于与4-1BBL的相互作用。在基因缺陷动物中,4-1BB的缺失导致T细胞对特异性抗原的反应性增强而不是抑制,并且4- 1BB缺陷小鼠自发地产生自身免疫型表型,在粘膜界面处具有慢性炎症,这是在4- 1BBL缺陷小鼠中未观察到的表型。我们的假设是,4-1BB与未鉴定的配体结合,这些配体在免疫应答早期组成性表达或诱导,以限制T细胞反应性并维持耐受性,但通过将伴侣转换为随后在炎症中表达的4-1BBL,4-1BB可以提供积极的刺激作用。我们的初步结果已经确定了半乳糖凝集素-3和半乳糖凝集素-9,两个报告的抑制分子,作为合作伙伴的4- 1BB。这项研究将调查半乳糖凝集素与4-1BB的相互作用,并确定4-1BB/半乳糖凝集素相互作用是否导致4-1BB负调节T细胞反应性。4-1BB的新结合伴侣的鉴定和表征将为4-1BB生物学以及T细胞耐受和慢性炎症提供新的理解。 公共卫生相关性:4-1BB及其配体在许多免疫细胞的表面上表达,并且被认为调节产生免疫应答的能力。4-1BB为T细胞提供必要的信号,使其在反应后期继续分裂,并抑制过度死亡。然而,4-1BB相互作用也是控制初始T细胞分裂和扩增的限速步骤。通过了解4-1BB及其配体在何处和何时表达,以及这些假定相互作用的功能重要性,我们将获得可能导致增强或抑制T细胞应答的方法的知识,因此可能在许多疾病环境中具有治疗相关性,例如限制自身免疫,或增强对癌细胞或感染性病原体的应答能力。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.
  • DOI:
    10.4049/jimmunol.1700575
  • 发表时间:
    2017-10-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Madireddi S;Eun SY;Mehta AK;Birta A;Zajonc DM;Niki T;Hirashima M;Podack ER;Schreiber TH;Croft M
  • 通讯作者:
    Croft M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Croft其他文献

Michael Croft的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Croft', 18)}}的其他基金

TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    10400699
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10531229
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
  • 批准号:
    9982199
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10053328
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    9910059
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
Treg 细胞固有的 CTLA4-PKC-eta 信号通路介导接触依赖性肿瘤免疫抑制:癌症免疫治疗的新靶点
  • 批准号:
    10310411
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
TWEAK and Skin Inflammation
调整和皮肤炎症
  • 批准号:
    10152528
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
  • 批准号:
    9788250
  • 财政年份:
    2018
  • 资助金额:
    $ 23.61万
  • 项目类别:
Training in Immunological Mechanisms
免疫机制培训
  • 批准号:
    9321444
  • 财政年份:
    2016
  • 资助金额:
    $ 23.61万
  • 项目类别:
Training in Immunological Mechanisms
免疫机制培训
  • 批准号:
    10675443
  • 财政年份:
    2016
  • 资助金额:
    $ 23.61万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政​​策的情绪动态
  • 批准号:
    10108433
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
  • 批准号:
    MR/X032809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341426
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341424
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
  • 批准号:
    2335955
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
  • 批准号:
    DP240103257
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
  • 批准号:
    DP240100408
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
  • 批准号:
    DP240100111
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
  • 批准号:
    502786
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Directed Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了